{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:14:10Z","timestamp":1785726850311,"version":"3.56.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006260","name":"Technion - Israel Institute of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006260","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40257-025-00998-w","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T10:01:38Z","timestamp":1772532098000},"page":"247-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mastering the Use of Systemic JAK Inhibitors for Atopic Dermatitis: A Dermatologist's Practical Guide"],"prefix":"10.1007","volume":"27","author":[{"given":"Ahmad","family":"Jalili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Labbouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-3798","authenticated-orcid":false,"given":"Roni P.","family":"Dodiuk-Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"10247","key":"998_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"issue":"1","key":"998_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.anai.2020.08.016","volume":"126","author":"N Puar","year":"2021","unstructured":"Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):21\u201331. https:\/\/doi.org\/10.1016\/j.anai.2020.08.016.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"998_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024;20(2):101\u201315. https:\/\/doi.org\/10.1038\/s41584-023-01062-9.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"998_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729\u201349. https:\/\/doi.org\/10.1007\/s13555-023-00892-5.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"998_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae342","author":"C Haag","year":"2024","unstructured":"Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, et al. A practical guide to using oral JAK inhibitors for atopic dermatitis from the International Eczema Council. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae342.","journal-title":"Br J Dermatol."},{"issue":"15","key":"998_CR6","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.3390\/molecules25153321","volume":"25","author":"A Coricello","year":"2020","unstructured":"Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside perspective of the synthetic and computational toolbox of JAK inhibitors: recent updates. Molecules. 2020;25(15):3321.","journal-title":"Molecules"},{"issue":"3","key":"998_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdermsci.2023.12.008","volume":"113","author":"S Inoue","year":"2024","unstructured":"Inoue S, Suzuki T, Sano S, Katayama I. Jak inhibitors for the treatment of vitiligo. J Dermatol Sci. 2024;113(3):86\u201392. https:\/\/doi.org\/10.1016\/j.jdermsci.2023.12.008.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"998_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","volume":"14","author":"AM Shawky","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14(5):1001.","journal-title":"Pharmaceutics"},{"key":"998_CR9","doi-asserted-by":"publisher","unstructured":"Esposito M, Guanti M.B, Morrone P, Napolitano M, Pezzolo E, Rossi M. Clinical Practice. 2024; Anno VI | n. 01. https:\/\/doi.org\/10.36160\/CP.2024.01","DOI":"10.36160\/CP.2024.01"},{"key":"998_CR10","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"IH Huang","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13:1068260.","journal-title":"Front Immunol"},{"issue":"4","key":"998_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semcdb.2008.07.020","volume":"19","author":"AF Wilks","year":"2008","unstructured":"Wilks AF. The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol. 2008;19(4):319\u201328.","journal-title":"Semin Cell Dev Biol"},{"issue":"2","key":"998_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli M, Kerschbaumer A, Kastrati K, et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2024;83(2):139\u201360. https:\/\/doi.org\/10.1136\/ard-2023-223850.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"998_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH. Clinical significance of Janus Kinase inhibitor selectivity [published correction appears in Rheumatology (Oxford). 2019 Jun 1;58(6):1122. doi: 10.1093\/rheumatology\/kez002]. Rheumatology (Oxford). 2019;58(6):953\u201362.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"998_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11926-020-00931-6","volume":"22","author":"V Reddy","year":"2020","unstructured":"Reddy V, Cohen S. JAK inhibitors: what is new? Curr Rheumatol Rep. 2020;22(9):50. https:\/\/doi.org\/10.1007\/s11926-020-00931-6.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"998_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","volume":"63","author":"PC Taylor","year":"2024","unstructured":"Taylor PC, Choy E, Baraliakos X, Szekanecz Z, Xavier RM, Isaacs JD, et al. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology (Oxford). 2024;63(2):298\u2013308.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"998_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"998_CR17","unstructured":"European Medicines Agency. Janus kinase inhibitors (JAKi) Article-20 procedure: EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders [Internet]. EMA; 2023 May 22. Report No.: EMA\/142279\/2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_en.pdf"},{"issue":"5","key":"998_CR18","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jaad.2024.06.087","volume":"91","author":"A Nohria","year":"2024","unstructured":"Nohria A, Desai D, Lee A, Karagounis T, Shapiro J, Garshick M, et al. Evaluating dermatologists\u2019 knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata. J Am Acad Dermatol. 2024;91(5):976\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"998_CR19","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1111\/ddg.14885","volume":"20","author":"A Eichner","year":"2022","unstructured":"Eichner A, Wohlrab J. Pharmacology of inhibitors of Janus kinases - Part 2: pharmacodynamics. JDDG J Dtsch Dermatol Ges. 2022;20(12):1621\u201331. https:\/\/doi.org\/10.1111\/ddg.14885.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"9","key":"998_CR20","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s13555-024-01243-8","volume":"14","author":"MG Kirchhof","year":"2024","unstructured":"Kirchhof MG, Prajapati VH, Gooderham M, Hong CH, Lynde CW, Maari C, et al. Practical recommendations on laboratory monitoring in patients with atopic dermatitis on oral JAK inhibitors. Dermatol Ther (Heidelb). 2024;14(9):2653\u201368. https:\/\/doi.org\/10.1007\/s13555-024-01243-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"998_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100195","volume":"3","author":"M Kamata","year":"2023","unstructured":"Kamata M, Tada Y. Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence. JID Innov. 2023;3(3):100195. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100195.","journal-title":"JID Innov"},{"key":"998_CR22","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.5346","volume":"103","author":"Y Han","year":"2023","unstructured":"Han Y, Woo YR, Cho SH, Lee JD, Kim HS. Itch and Janus Kinase inhibitors. Acta Derm Venereol. 2023;103:adv00869. https:\/\/doi.org\/10.2340\/actadv.v103.5346.","journal-title":"Acta Derm Venereol"},{"key":"998_CR23","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, Brough HA, Calzavara-Pinton P, Christen-Zaech S, Deleuran M, Dittmann M, Fosse N, G\u00e1sp\u00e1r K, Gerbens LAA, Gieler U, Girolomoni G, Gregoriou S, Holland S, Mortz CG, Nast A, Nygaard U, Rehbinder EM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Werner RN, Flohr C. European Guideline (EuroGuiDerm) on atopic eczema: Living update. J Eur Acad Dermatol Venereol. 2025.","DOI":"10.1111\/jdv.20639"},{"issue":"2","key":"998_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2013.10.010.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"998_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87(4):784\u201391.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"998_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312.","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"1","key":"998_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40744-020-00275-8","volume":"8","author":"A Walton","year":"2021","unstructured":"Walton A, Paik J, Quebe A, Kannowski CL, Choong C, Anderson S, et al. Frequency of prescription claims for drugs that may interact with Janus kinase inhibitors among patients with rheumatoid arthritis in the US. Rheumatol Ther. 2021;8(1):599\u2013607.","journal-title":"Rheumatol Ther"},{"key":"998_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15636","volume":"35","author":"H Wan","year":"2022","unstructured":"Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther. 2022;35:e15636.","journal-title":"Dermatol Ther"},{"key":"998_CR29","volume":"11","author":"JJ Pereyra-Rodriguez","year":"2021","unstructured":"Pereyra-Rodriguez JJ, Alcantara-Luna S, Dom\u00ednguez-Cruz J, Gal\u00e1n-Guti\u00e9rrez M, Ruiz-Villaverde R, Vilar-Palomo S, et al. Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis. Life (Basel). 2021;11:927.","journal-title":"Life (Basel)"},{"issue":"2","key":"998_CR30","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"998_CR31","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"key":"998_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400:273\u201382.","journal-title":"Lancet"},{"issue":"1","key":"998_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735. https:\/\/doi.org\/10.1136\/rmdopen-2022-002735.","journal-title":"RMD Open"},{"issue":"4","key":"998_CR34","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol. 2024;25(4):639\u201354. https:\/\/doi.org\/10.1007\/s40257-024-00869-w.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"998_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218398.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"998_CR36","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s13555-024-01200-5","volume":"14","author":"MJ Gooderham","year":"2024","unstructured":"Gooderham MJ, de Bruin-Weller M, Weidinger S, Cork MJ, Eichenfield LF, Simpson EL, et al. Practical management of the JAK1 inhibitor abrocitinib for atopic dermatitis in clinical practice: special safety considerations. Dermatol Ther (Heidelb). 2024;14(8):2285\u201396.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"998_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2276043","volume":"34","author":"T Hagino","year":"2023","unstructured":"Hagino T, Yoshida M, Hamada R, Saeki H, Fujimoto E, Kanda N. Effectiveness of switching from baricitinib 4\u2009mg to upadacitinib 30\u2009mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. J Dermatolog Treat. 2023;34(1):2276043. https:\/\/doi.org\/10.1080\/09546634.2023.2276043.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"998_CR38","first-page":"162","volume":"31","author":"S Mastraftsi","year":"2023","unstructured":"Mastraftsi S, Bakakis M, Tsiogka A, Afroditi Kleidona I, Gregoriou S. Switching between JAK inhibitors in patients with atopic dermatitis: unanswered questions in daily clinical practice. Acta Dermatovenerol Croat. 2023;31(3):162\u20134.","journal-title":"Acta Dermatovenerol Croat"},{"key":"998_CR39","unstructured":"NICE Clinical Knowledge Summary. Tuberculosis | Diagnosis | Screening. Available from https:\/\/cks.nice.org.uk\/topics\/tuberculosis\/diagnosis\/screening. Accessed 29 November 2024."},{"key":"998_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0026-2016","author":"CC Dobler","year":"2016","unstructured":"Dobler CC. Biologic agents and tuberculosis. Microbiol Spectr. 2016. https:\/\/doi.org\/10.1128\/microbiolspec.TNMI7-0026-2016.","journal-title":"Microbiol Spectr"},{"key":"998_CR41","unstructured":"Centres for Disease Control and Prevention. Clinical Testing Guidance for Tuberculosis: Tuberculin Skin Test | Tuberculosis (TB) | CDC. Available from https:\/\/www.cdc.gov\/tb\/hcp\/testing-diagnosis\/tuberculin-skin-test.html. Accessed 29 Nov 2024."},{"issue":"4","key":"998_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40261-024-01353-3","volume":"44","author":"M Chaparro","year":"2024","unstructured":"Chaparro M, Ceballos D, Vicente R, Gisbert JP. Experience of tofacitinib use in pregnancy in patients with ulcerative colitis. Clin Drug Investig. 2024;44(4):285\u20138.","journal-title":"Clin Drug Investig"},{"issue":"24","key":"998_CR43","doi-asserted-by":"publisher","first-page":"03274","DOI":"10.1016\/j.jaad.2024.10.108","volume":"S0190\u20139622","author":"ER Gordon","year":"2024","unstructured":"Gordon ER, Hanson M, Bhutani T, Mesinkovska NA. Current evidence on safety of JAK inhibitors in pregnancy and lactation. J Am Acad Dermatol. 2024;S0190\u20139622(24):03274\u201382. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.108.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"998_CR44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S2468-1253(23)00158-9","volume":"8","author":"M Julsgaard","year":"2023","unstructured":"Julsgaard M, Mahadevan U, Vestergaard T, Mols R, Ferrante M, Augustijns P. Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis. Lancet Gastroenterol Hepatol. 2023;8(8):695\u20137.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"998_CR45","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","volume":"14","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, Burroni AG, Chiricozzi A, Dapavo P, et al. Management of patients affected by moderate-to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: an Italian Delphi consensus. Dermatol Ther (Heidelb). 2024;14(4):919\u201332. https:\/\/doi.org\/10.1007\/s13555-024-01135-x.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"998_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jaad.2022.08.040","volume":"88","author":"RA Waldman","year":"2023","unstructured":"Waldman RA, Sharp KL, Adalsteinsson JA, Grant-Kels JM. Herpes zoster subunit vaccine for patients initiating a Janus kinase inhibitor. J Am Acad Dermatol. 2023;88(3):697\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"998_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdin.2021.11.001","volume":"6","author":"N Katoh","year":"2022","unstructured":"Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K, et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (rising up): an interim 24-week analysis. JAAD Int. 2022;6:27\u201336.","journal-title":"JAAD Int"},{"key":"998_CR48","unstructured":"Centres for Disease Control and Prevention. Shingles Vaccine Recommendations. Available from Shingles Vaccine Recommendations | Shingles (Herpes Zoster) | CDC. Accessed 29 November 2024."},{"issue":"4","key":"998_CR49","first-page":"4","volume":"28","author":"L Guenther","year":"2023","unstructured":"Guenther L. Prevention of shingles in dermatology patients on systemic medications. Skin Therapy Lett. 2023;28(4):4\u20136.","journal-title":"Skin Therapy Lett"},{"issue":"3","key":"998_CR50","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133\u201345.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"998_CR51","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","volume":"12","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12(1):7140. https:\/\/doi.org\/10.1038\/s41598-022-10777-w.","journal-title":"Sci Rep"},{"key":"998_CR52","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145:877\u201384.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"998_CR53","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476\u201385. https:\/\/doi.org\/10.1111\/jdv.16948.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10139","key":"998_CR54","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, den Van Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2.","journal-title":"Lancet"},{"issue":"10290","key":"998_CR55","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"issue":"11","key":"998_CR56","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1001\/jamadermatol.2022.3516","volume":"158","author":"TL Chen","year":"2022","unstructured":"Chen TL, Lee LL, Huang HK, Chen LY, Loh CH, Chi CC. Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(11):1254\u201361. https:\/\/doi.org\/10.1001\/jamadermatol.2022.3516.","journal-title":"JAMA Dermatol"},{"key":"998_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdcr.2022.09.029","volume":"30","author":"SD Lee","year":"2022","unstructured":"Lee SD, Ahn HJ, Shin MK. A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis. JAAD Case Rep. 2022;30:11\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2022.09.029.","journal-title":"JAAD Case Rep"},{"key":"998_CR58","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/jdv.18027","volume":"36","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Nymand LK, Maul JT, Schmid-Grendelmeier P, Wu JJ, Thomsen SF, et al. Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. J Eur Acad Dermatol Venereol. 2022;36:890\u20136. https:\/\/doi.org\/10.1111\/jdv.18027.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"998_CR59","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","volume":"159","author":"J Martinez","year":"2023","unstructured":"Martinez J, Manjaly C, Manjaly P, Ly S, Zhou G, Barbieri J, et al. Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(12):1339\u201345. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3830.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"998_CR60","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1111\/1346-8138.16116","volume":"48","author":"PH Chang","year":"2021","unstructured":"Chang PH, Huang SF, Chang PS, Yu Y. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications. J Dermatol. 2021;48(11):1631\u20139.","journal-title":"J Dermatol"},{"key":"998_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17501","author":"PA Ireland","year":"2024","unstructured":"Ireland PA, Verheyden M, Jansson N, Sebaratnam D, Sullivan J. Infection risk with JAK inhibitors in dermatoses: a meta-analysis. Int J Dermatol. 2024. https:\/\/doi.org\/10.1111\/ijd.17501.","journal-title":"Int J Dermatol."},{"issue":"3","key":"998_CR62","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","volume":"18","author":"MA Adas","year":"2022","unstructured":"Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18(3):253\u201361.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"998_CR63","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/1744666X.2022.2039122","volume":"18","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R. Recent issues in JAK inhibitor safety: perspective for the clinician. Expert Rev Clin Immunol. 2022;18(3):295\u2013307.","journal-title":"Expert Rev Clin Immunol"},{"key":"998_CR64","unstructured":"Grundy SM, Feingold KR. Guidelines for the Management of High Blood Cholesterol. 2022 May 28. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferr\u00e8re B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000\u2013. PMID: 26247090. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK305897\/. Accessed 30 Nov 2024."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00998-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:19:44Z","timestamp":1774696784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00998-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["998"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00998-w","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent to Publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Ahmad Jalili has been involved in consultancy, lectures and\/or clinical trials for AbbVie, Almirall, Amgen , Bayer, BioMed, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galderma, GlaxoSmithKline, Incyte Biosciences, Janssen-Cilag, La Roche-Posay, LEO Pharma, Merz Pharma, MSD, Novartis, Pfizer, Sanofi, Sandoz, UCB Pharma. Roni Dodiuk-Gad has been a consultant and\/or investigator for Abbvie, Dexcel, Devintec Pharma, Eli Lilly, Janssen, La Roche-Posay, Mitsubishi Tanabe Pharma America, Novartis, Pfizer, Sanofi, Sol-Gel Technologies Ltd. Melinda Gooderham has been an investigator, speaker and\/or advisor for AbbVie, Acelyrin, Alumis, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Cara, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, JAMP Pharma, Janssen, LEO Pharma, L\u2019Oreal, MedImmune, Meiji, Moonlake, Nektar, Nimbus, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tarsus, Takeda, UCB, Union, Ventyx and Vyne. Dr Michael Ziv has served as an investigator, speaker, and consultant for AbbVie, Sanofi, Novartis, Eli Lilly, Boehringer-Ingelheim, Janssen, Pfizer, DermAbio, and Neopharm. Sofia Labbouz: none.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All authors made substantial contributions to the conception or design of the work, drafted the work or revised it critically for important intellectual content, approved the version to be published, and agree to be accountable for all aspects of the work. All authors read and approved the final manuscript. *Based on\/adapted from: ICMJE, Defining the Role of Authors and Contributors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}